Reaction
Blast Crisis In Myelogenous Leukaemia reporting signals
As of the last recalculation, Blast Crisis In Myelogenous Leukaemia appears in 1,221 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB (PRR 296.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Imatinib | 245 | 296.0 | 300.2 |
| Nilotinib | 255 | 186.1 | 187.7 |
| Imatinib Mesylate | 181 | 129.7 | 130.6 |
| Dasatinib | 148 | 77.1 | 77.4 |
| Bosutinib | 38 | 74.4 | 74.7 |
| Hydroxyurea | 74 | 63.4 | 63.7 |
| Busulfan | 14 | 15.3 | 15.3 |
| Cytarabine | 40 | 11.7 | 11.7 |
| Blinatumomab | 6 | 9.8 | 9.9 |